Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

NCT06490081 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Myelosuppression

Interventions

DRUG: Trilaciclib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences